Not medical advice. The Journal of Biohacking reports published research and teaching models. Nothing on this page is medical advice, a diagnosis, or a recommendation to use any compound, product, or therapy. Where a dose appears, it is a figure reported in a cited study or by its sponsor, not an instruction. Editorial position on dosing.
Journal of Biohacking · Research Corpus · Prepared 30 Oct 2026 (America/Los_Angeles)
Beyond baseline. Graded honestly.
An evidence-graded synthesis of the biohacking frontier — from PubMed, reviews, niche sources, and community discourse labelled as anecdotal — for a publication whose mission is not returning people to baseline, but helping them go beyond it. Every grade below is for the optimization / healthy-longevity claim, not for a disease indication.
7 domains12 hallmarks of aging (Cell 2023)Inline PMIDs & sourcesCommunity = [ANECDOTAL]Research synthesis — not medical advice
The one-sentence finding
No drug, peptide, or supplement in this corpus has been shown in a randomized human trial to extend lifespan or slow aging in healthy people. The strongest statement supported everywhere is narrower: specific interventions move specific biomarkers or functions, in specific populations, for weeks to months.
EstablishedReplicated human RCTs / meta-analyses, meaningful effect, relevant population.
Emerging≥1 human RCT; promising but small, short, surrogate, single-sponsor, or primary-endpoint-missed.
SpeculativeAnimal / in-vitro / pharmacokinetic or uncontrolled human data only.
FolkloreNo credible human efficacy data, retracted/never-published source, or marketing that contradicts the trial record.
Start here
The corpus in 7 points
01
The boring levers win
Cardiorespiratory fitness / VO2max training, sleep regularity & light-dark timing, and warm-bath timing have human effect sizes and cohort sizes (n=60,977–122,007 for observational anchors; replicated RCTs for training and light) that dwarf every pill in §§1–3.
02
NAD⁺ rises. Function doesn't reliably follow.
NR/NMN raise blood NAD⁺ in every competent trial; pooled functional benefits (strength, glucose, cognition) are null or inconsistent. Urolithin A is the partial exception — real strength/endurance signals, but both flagship RCTs missed their primary endpoints.
03
Senolytics: target hit, benefit unproven
D+Q cleared p16/p21-positive cells in 9 people (2019); its first proper RCT (n=60, 2024) missed its primary endpoint.
04
The peptide economy runs on animal data
BPC-157: 35 preclinical vs 1 clinical study in a 2024 systematic review. TB-500, injectable GHK-Cu, MOTS-c, epitalon, DSIP: zero modern controlled human efficacy trials between them.
05
Rapamycin: strongest animal, unproven human
PEARL (2025), the first year-long RCT, was null on its primary endpoint and confounded by a low-bioavailability compounded formulation and sponsor conflict.
06
Two longevity drugs trade off against training
Metformin blunted resistance- and aerobic-training adaptations in two independent RCTs in older adults — directly relevant to a publication preaching beyond baseline.
How to read this briefing
An intervention can be Established for a disease indication and simultaneously Speculative for enhancing a healthy person. That distinction explains most of the hype gap. Community material is explicitly tagged [ANECDOTAL]. PMIDs are given where the consulted source reported them.
Interactive · Highest leverage visual #1
The electron transport chain
Every §1 product touches this one machine. Tap an intervention to see where it acts — and what the human data actually show.
Model is illustrative of direction from the corpus, not a measured simulation. With age: NAD⁺ falls (CD38, PARPs consume; NAMPT synthesis declines), damaged mitochondria accumulate as mitophagy (PINK1/Parkin) slows, and biogenesis signalling (PGC-1α → NRF1/2 → TFAM) weakens.
Mechanism: NR → NMN → NAD⁺ (salvage pathway). NAD⁺ required by sirtuins, PARPs, redox reactions.
NR 1,000 mg/day × 6 wks, crossover n=30 enrolled / 24 completed, age 55–79: NAD⁺ ~+60%, well tolerated; BP/arterial-stiffness exploratory, strongest in stage-1 hypertension subgroup — Martens et al., Nat Commun 2018, via NutraIngredients.
NMN n=80, 300/600/900 mg/day × 60 days: blood NAD⁺ & 6-min walk rose vs placebo at all doses, highest at 600–900 mg — Yi et al., Geroscience 2023, PMID 36482258, via Healthspan Post.
Head-to-head n=65, 14 days: NR & NMN comparably raised circulatory NAD⁺; nicotinamide did not — Christen et al., Nat Metab 2026, PMID 41540253.
Key negative: NR 2,000 mg/day × 12 wks, n=40 obese insulin-resistant men: no improvement in clamp insulin sensitivity, glucose disposal, body composition or energy expenditure despite raising NAD⁺ — Dollerup et al., Am J Clin Nutr 2018, via AntiAgingBrain. NR in MCI raised NAD⁺ without improving cognition (Orr 2024). Pooled >60y: no clear benefit for muscle mass, grip or walking speed.
Animal caution: NR showed no lifespan benefit in NIA ITP mice (Espinoza 2023).
Safety: Well tolerated ≤12 wks; no severe AEs at 1,250 mg/day × 4 wks (n=31). Long-term >1 yr, cancer-context, pregnancy: absent. [ANECDOTAL] Community: 500–1,000 mg NMN or 300–1,000 mg NR daily, often + TMG (methyl-donor theory, untested in humans).
Mechanism: Gut metabolite of pomegranate/walnut ellagitannins; induces PINK1/Parkin mitophagy. Only a minority convert dietary ellagitannins efficiently — rationale for direct supplementation (Mitopure).
First-in-human: safe, bioavailable, muscle mitochondrial gene-expression signature after 4 wks at 500–1,000 mg — Andreux et al., Nat Metab 2019, via FoundMyFitness.
ATLAS n=88 untrained overweight 40–64y, 500/1,000 mg × 4 mo: hamstring strength +~12% vs placebo, acylcarnitines & CRP fell, biopsy mitophagy proteins rose — but primary endpoint (peak power) did not improve significantly — Singh et al., Cell Rep Med 2022, PMID 35584623, via Kymata Health. Sponsor: Amazentis, employing most authors.
Older adults n=66, 65–90y, 1,000 mg × 4 mo: muscle endurance improved; 6-min walk & maximal ATP production did not — Liu et al., JAMA Network Open 2022, PMID 35050355.
Systematic review 2024 (5 studies, n=250): no effect on maximal ATP production, biogenesis, body composition or physical-function tests (PMID 39002645, via No1gevity). In trained runners n=42, no 3,000 m improvement.
Safety: No major signals ≤1,000 mg/day ≤4 mo; long-term absent. [ANECDOTAL] 500–1,000 mg/day as “exercise-in-a-pill” — trials were in untrained people.
CoQ10
Established · HF only
Mechanism: Ubiquinone/ubiquinol shuttles electrons I/II → III; lipid antioxidant. Falls with age & statins.
Q-SYMBIO n=420, HF NYHA III–IV, 100 mg TID × 2 yrs: MACE 15% vs 26% (HR 0.50, 95% CI 0.32–0.80), CV death 9% vs 16%, all-cause death 10% vs 18%; 16-wk endpoints null — Mortensen et al., JACC Heart Fail 2014, PMID 25282031, via SupplementScore.
Fertility: 2024 meta, 6 RCTs, n=1,529 diminished ovarian reserve — higher pregnancy & oocyte yield with pretreatment, via East to West Fertility.
Safety: Very well tolerated; interacts with warfarin, can lower BP slightly. Community: 100–300 mg ubiquinol daily. Grade: Established as HF adjunct; Speculative for optimization.
PQQ + the benchmark
Speculative
PQQ: Rodent PGC-1α / biogenesis claim. Human: small Japanese trials, largest n≈64; 20–21.5 mg/day improved some cognitive domains in one RCT — no human trial has measured mitochondrial biogenesis, density, or function. Review via No1gevity & PMC11541945 as cited there. [ANECDOTAL] 10–20 mg/day + CoQ10 on slogan “PQQ builds, CoQ10 runs” — no human mechanistic verification.
The benchmark everyone skips: Training increases PGC-1α, mitochondrial respiration & mitophagy flux in human muscle in controlled trials. Konopka 2019: aerobic training raised muscle mitochondrial respiration ~25% in older adults in the placebo arm. Established
Domain 2
Cellular senescence
Senescent cells exit the cycle (p16/p21 ↑), resist death via SCAPs, and secrete the SASP — IL-1α, IL-6, IL-8, MMPs — driving inflammaging & paracrine senescence. Senolytics kill them (hit-and-run). Senomorphics mute the SASP.
Senolytic vs senomorphic — try it
Senolytic: the senescent cell dies. Benefit if clearance helps; cost: you also lose beneficial senescence functions — wound healing & tumour suppression. Dosing is intermittent because cells re-accumulate slowly.
Dasatinib + Quercetin (D+Q) Emerging
Target engagement: n=9 diabetic kidney disease, D 100 mg + Q 1,000 mg × 3 days — at day 11 adipose p16⁺ −35%, p21⁺ −17%, SA-β-gal⁺ −62%, crown-like structures −86%, skin p16⁺ −20%; IL-1α/IL-6/MMP-9/MMP-12 fell — Hickson et al., EBioMedicine 2019, PMID 31542391 — PubMed. No control, no clinical endpoint.
First RCT (missed): n=60 postmenopausal women, 3 days q28d ×5 over 20 wks — primary CTx did not differ (p=0.611); P1NP rose transiently wks 2–4 only; exploratory benefit in high-burden subgroup — Farr et al., Nat Med 2024, via GreyArea Labs.
Newest signal — treat cautiously: n=31 fibrotic MASH, fibrosis ≥1 stage without worsening 47% vs 7% — Koning et al., Nat Metab, 1 Oct 2026, via same GreyArea summary. One small disease trial.
Field at Oct 2026: only 9 senolytic trials published, only 2 controlled (Mayo analysis via Resilienz12).
Safety — serious caveat: Dasatinib is a leukaemia drug (myelosuppression, bleeding, pleural effusion, QT). In Farr 2024 AEs 23/30 vs 5/30 controls (headache, diarrhoea, nausea, fatigue; 1 QT withdrawal), no serious AEs in that trial. [ANECDOTAL] Self-sourced pulses q1–3 mo; quercetin alone 250–500 mg/day is not the studied intervention.
Fisetin Speculative
Strongest senolytic flavonoid in 2018 Mayo screen; extended mouse health/lifespan in that report (Yousefzadeh et al., EBioMedicine 2018). Disconfirming anchor: NIA ITP found no lifespan extension for fisetin (via No1gevity).
Human: small Mayo pilot — SASP MMP-3/TGF-β1 & senescent PBMCs fell, T-cell burden unchanged. AFFIRM / AFFIRM-LITE (~40 each) had no results posted as of 21 Oct 2026; vascular trial NCT06133634 likewise unreported.
Mouse senolytic dose ~100 mg/kg pulsed dwarfs label 100–500 mg — supplement-dose senolysis biologically implausible on current PK. [ANECDOTAL] ~20 mg/kg ×2–3 days monthly copied from mouse conversions; Blueprint ~200 mg/day self-reported, predating ITP null.
Senomorphics & navitoclax
Rapamycin (mTORC1 → IL-1α/NF-κB), metformin (AMPK/NF-κB), ruxolitinib — mechanistic attributions, no human trial proving SASP suppression → clinical benefit (Delrue et al., Int J Mol Sci 2025, PMC12524491). Navitoclax: potent preclinically, thrombocytopenia dose-limiting. Unity Biotechnology voted to dissolve in 2025 after lead failures. Speculative
Domain 3 · Honesty table
Peptides
Most are sold as “research chemicals,” on FDA 503A Category 2 (2023, incl. BPC-157) and WADA-prohibited. July 2026 FDA advisory voted non-bindingly to loosen compounding for several (BPC-157 8–6; DSIP rejected 6–7) against FDA scientists’ advice — regulatory loosening is not efficacy evidence. Source: Aging With Strength.
Peptide
Human efficacy trials
Best human data
Grade
BPC-157
0 RCTs
Retrospective knee series n=12–16
Speculative
TB-500
0
None for TB-500 itself
Folklore→Speculative
GHK-Cu injectable
0
None; topical cosmetic small studies only
Speculative topical: Emerging
MOTS-c
0 (of peptide itself)
Analog trial, defunct sponsor
Speculative
Epitalon
0 modern controlled
Single-group Russian cohorts
Speculative
CJC / ipamorelin
0 outcome RCTs
GH/IGF-1 pharmacodynamics only
Speculative
Tesamorelin (comparator)
Phase III, n=806
VAT −15–18% in HIV lipodystrophy
Established — that indication only
BPC-157 — fewer than 30 people
2024 systematic review: 544 screened, 36 included — 35 preclinical, 1 clinical (retrospective knee, 7/12 reported improvement, no controls/objective outcomes). Plus interstitial-cystitis pilot n=12 & 2025 IV safety n=2. 2015 Phase I n=42 never published. Sources: Ordinary Peptides; McGill OSS.
[ANECDOTAL, systematically collected] Reddit qualitative study (20 subreddits incl. r/Biohackers, r/BPC_157): 537 side-effect posts — injection-site, diarrhoea, repeated anhedonia/apathy reports (ResearchGate). Community: 250–500 mcg SC 1–2×/day, 4–8 wks; “Wolverine stack” + TB-500 tested once in rats — TB-500 alone did as well, adding BPC added nothing (The Peptide App).
TB-500 · GHK-Cu · MOTS-c · Epitalon
TB-500: Fragment of thymosin β4. Zero human trials of TB-500 itself; safety completely unknown (Ordinary Peptides). Do not borrow credibility from RGN-259 (full-length Tβ4 eye drops). Community: 2–5 mg SC 2×/wk loading.
GHK-Cu: ~99 PubMed papers, Sept 2026 RCT filter returned none. Topical n=20–50 cosmetic studies; post-laser RCT: no significant objective improvement. Injectable never studied in humans. Sources: PeptideNav.
MOTS-c: No trial of MOTS-c itself. Analog CB4211 n=88 ×28 days: safety cleared, no clear benefit, sponsor dissolved. Epitalon: One group only (Khavinson), 15-yr cohort lower mortality, no randomization/replication; telomerase in cell lines only — also the oncological concern.
CJC-1295 / ipamorelin
Teichman 2006: CJC-1295 (DAC) dose-dependent GH/IGF-1 lasting days, no serious AEs short-term. No Phase III, no body-composition/strength/sleep/longevity RCT (Outliyr). Ipamorelin human development for post-op ileus: Phase 2 safe but missed endpoint, discontinued (Amino101). Community: 100–300 mcg each, fasted, pre-bed/post-workout, 5-on/2-off — described by sources themselves as community practice, not a validated protocol.
Class safety: Chronic GH/IGF-1 ↑ linked to insulin resistance, carpal tunnel, arthralgia, proliferative risk; grey-market protocols omit the IGF-1 monitoring tesamorelin's label mandates.
Tesamorelin — the honest comparator
Pooled Phase III n=806, HIV lipodystrophy: visceral fat −15 to −18% vs placebo at 26 wks, maintained at 52 wks on treatment, rebounding on discontinuation. Costs: IGF-1 monitoring, fluid retention, glucose intolerance (one summary: new-onset diabetes HR ~3.3), contraindication in active malignancy. Sources: Atlas; Peptides Explorer. Proves the axis can change body composition in disease — does not validate CJC/ipamorelin in healthy people.
Domain 4
Metabolic optimization
mTOR: the timing argument — drag the schedule
Rapamycin thesis: acute mTORC1 inhibition (autophagy on, growth off, SASP translation off) vs chronic spillover to mTORC2 (insulin resistance, lipids, immunosuppression). This simulator shows the concept from the corpus, not a pharmacokinetic model.
Daily transplant doseWeekly low doseNo drug
Rapamycin Emerging safety · Speculative benefit
ITP anchor: lifespan extension in heterogeneous mice even started ~600 days (≈60 human yrs), originally +9–14% (Harrison et al., Nature 2009, via Rapamycin News).
PEARL: 48-wk decentralized DB RCT, NCT04488601, n=114 completers (129 enrolled), 50–85y, 5 vs 10 mg compounded weekly vs placebo. Primary (visceral adiposity DXA): null, p=0.942. Secondary: lean mass (ηp²=0.202, p=0.013), pain in women on 10 mg, well-being on 5 mg — Zalzala et al., Aging 2025, PMID 40188830, PubMed. Confounds: compounded bioavailability ~⅓ generic; senior authors employed by / hold shares in AgelessRx (via Longetic).
2024 review (19 human studies): immune/CV/skin some improved; endocrine/muscular/neuro did not. RAPA-EX-01 summary (n=40, 6 mg weekly): no exercise-gain improvement, more AEs — secondary summary pending primary verification. [ANECDOTAL] Community 3–10 mg weekly, self-monitoring lipids/HbA1c; forum reports note LDL/TG & HbA1c rises.
Metformin Speculative for longevity
Established for T2D. ITP: metformin alone did not extend mouse lifespan. TAME: designed n≈3,000, 65–79y — sources conflict (see Open Questions): no TAME results exist.
ITP: median lifespan +~17–22% males, +~5% females; rapamycin+acarbose ~+28–34% (among largest ITP combos). Human longevity: none. Established only for postprandial glucose blunting in diabetes. Flatulence/diarrhoea dose-limiting. [ANECDOTAL] 25–100 mg with carb meals + CGM feedback.
CGM in non-diabetics Speculative / Folklore
Meta 23 studies, n=1,074 (Liao 2026): benefit in prediabetes; “no appreciable glycemic benefit in healthy normoglycemic populations,” no weight effect — via CGM evidence brief (PDF). CGM overestimated time >7.8 mmol/L ~4-fold vs capillary in one crossover; healthy people spend ~97–98% at 70–180 mg/dL, mean ~102 mg/dL. FDA OTC clearance 2024 = device clearance, not efficacy proof. Defensible: short-term feedback tool, esp. prediabetes; post-meal walking ↓ postprandial insulin ~29% in one CGM-guided RCT (via Pravida). Harms: anxiety, pathologizing normal excursions.
Zone 2 & VO2max — the Established core Established
Mandsager et al., JAMA Network Open 2018: n=122,007 treadmill-tested, median 8.4-yr follow-up — fitness inversely, dose-dependently associated with mortality, no observed upper limit; elite (≥97.7th %ile) HR 0.20 vs low; each +1 MET (≈3.5 mL/kg/min) ~12–15% lower mortality (via AskVora). Observational, but consistent + training RCTs on phenotype.
Trainability: sedentary adults typically +15–20% in months; HERITAGE response heritability ~40–50%. Norwegian 4×4 raised VO2max 7.2% in 8 wks even in fit runners. Zone 2 (~60–70% HRmax, lactate <2 mmol/L) enables volume in polarized ~80/20 model. Honest grade: polarized training & trainability Established; “Zone 2” as uniquely magical branded zone = Emerging — no RCT shows it beats volume/intensity-matched alternatives. Community: 150–300 min/wk zone 2 + 1× 4×4; wearable VO2max ±~10% vs lab.
Domain 5
Sleep & circadian engineering
Regularity beats duration* Emerging
Windred et al., Sleep 2024: UK Biobank n=60,977, >10M hrs, mean 62.8y, ~6.3-yr follow-up, 1,859 deaths. Sleep Regularity Index predicted mortality more strongly than duration: top quintiles 20–48% lower mortality; most-adjusted top HR 0.70 (0.59–0.83); adding duration didn't improve fit (p=0.14–0.20). Via Longevity Ladder. Second cohort n=72,269: irregular timing → more MI/stroke even at recommended duration.
*Observational only; 1 wk actigraphy; 97% white older cohort; illness/shift work cause irregularity (reverse causation). No RCT shows regularizing sleep extends life.
Light Established physiology
ipRGC (melanopsin) → SCN is dominant zeitgeber; timed bright light shifts phase 1–3 h/day, suppresses melatonin; accepted for circadian disorders & SAD. Shift-worker meta (11 studies, Sci Rep 2025, PMC11696139): total sleep +32.5 min, efficiency +2.9%. Human period ~24.2 h (Czeisler 1999).
Folklore layer: Exact protocol minutes (5 min sunny / 10 cloudy / 20–30 overcast, “100,000 lux before 9 a.m.”, cortisol-timer framing from n=8 lab study) are rules of thumb never tested as such — audit via NSDR. Evening dimming better supported than morning minute-counts.
Temperature Established · warm bath
Meta (Haghayegh et al., Sleep Med Rev 2019, PMID 31102877, PubMed): 17 studies from 5,322 screened; 40–42.5 °C, 1–2 h before bed, ≥10 min → sleep-onset latency −~10 min, quality/efficiency ↑. Mechanism: vasodilation → faster core-temp decline.
Cooling: 3-centre PSG n=72, high-heat-capacity mattress: N3 +7.5 min/night (p=0.0038), HR −2.36 bpm (p<0.0001), via JoVE. Device-specific RCTs small/absent; wearable “+% deep sleep” exceeds PSG evidence. Emerging for devices
DSIP & sleep peptides Speculative / Folklore
DSIP: Isolated 1974; human studies small, decades old, IV, contradictory — two placebo-controlled trials little/no benefit; half-life ~7–8 min; FDA advisory voted against DSIP compounding July 2026 (6–7). Sources: Peptide Register; Regen Health. Epitalon sleep claims: single group, no controlled sleep trial. CJC/ipamorelin: ipamorelin itself has no sleep trial. What has RCT support: CBT-I, timed light, warm bath, exercise & caffeine/alcohol timing.
Domain 6
Neurocognitive
Cerebrolysin Speculative for enhancement
Porcine-brain peptide mixture, IV, approved >50 countries (not FDA). Stroke Cochrane 2023 (7 RCTs, n=1,773): death RR 0.96 NS and non-fatal serious AEs RR 2.39 (1.10–5.23), RR 2.87 at 30 mL ×10d (PMID 37818733, via Peptide Report). Vascular dementia Cochrane 2019 (6 RCTs, n=597): cognition SMD 0.36, all very-low certainty. Healthy enhancement: zero evidence.
Dihexa — folklore formation Folklore
Zero published human trials, ever. “7,000,000× more potent than BDNF” is a cell-culture number from a paper reported as retracted April 2025 for fabricated image data; class relative fosgonimeton trial failed (p=0.70) — as reported in secondary investigation (Peptide List). Verify retraction specifics against the journal / Retraction Watch before republication — the “no human data” fact is uncontested. HGF/c-Met is a cancer pathway, unexamined in humans. Semax/Selank: small Russian trials, no large Western replication; N-acetyl Semax amidate has no PubMed literature of its own. Speculative
What has RCT support — modest & specific
Caffeine ± L-theanine — Established (acute): 40–300 mg improves alertness/attention acutely; 150 mg + theanine 250 mg improved some measures beyond caffeine alone (Haskell 2008, PMID 18006208, via Veedma). Hours-long performance, not baseline enhancement; borrows from sleep if late.
Creatine — Emerging: Meta 16 RCTs, n=492: memory SMD 0.31, attention/processing-speed time improved; overall cognition/executive null; larger in older, disease, vegetarian, sleep-deprived (Xu 2024, PMID 39070254, via SupplementScore). 3–5 g/day.
Bacopa — Emerging: Meta 9 RCTs (≥12 wks): speed of attention ↑ (Kongkeaw 2014, PMID 24252493).
Not supported: racetams (no modern healthy RCTs), proprietary stacks (combinations untested — “stacks” as sold = Folklore), alpha-GPC (limited data; large Korean cohort linked chronic use to higher stroke risk — observational, contested).
Intranasal insulin Folklore for healthy use
Pilot Craft 2011/12 n=104 MCI/AD, 20/40 IU ×4 mo: 20 IU delayed memory ↑, FDG-PET progression slowed. Definitive SNIFF Phase 2/3 (Craft, JAMA Neurol 2020, n≈289, 12 mo): primary outcomes did not differ from placebo — device-malfunction caveat for first cohort, exploratory second-device signals. APOE-ε4 subgroup flips across studies = post-hoc warning, not personalization. Healthy enhancement: no trials. Grade: Emerging→Speculative for MCI/AD (negative pivotal); Folklore for biohacker use.
Domain 7 · The hub visual
The cell itself: 12 hallmarks of aging
López-Otín et al., Cell 2013 (9) → Cell 2023, 186:243–278 (12). A hallmark must manifest in normal aging, accelerate aging when aggravated, and slow/reverse aspects when ameliorated. Tap a hallmark for what changes. Sources: IQ Healthspan; HormoneSynergy. A 2025 López-Otín & Kroemer paper proposed 2 more (ECM changes, psychosocial isolation) — proposal, not consensus, via TimeWarp.
Select a hallmark
Primary (1–3: damage) · Antagonistic (responses to damage, beneficial young / harmful old) · Integrative (system-level consequences). Interventions almost never touch one hallmark in isolation — both the promise and the marketing loophole of “targets X hallmarks.”
Diabetes/HF/pharmacodynamic data only for aging claims
Speculative (aging)
Teaching point: No intervention has demonstrated, in humans, reversal of a primary hallmark with clinical benefit attached. Epigenetic-clock movements are measurements, not validated surrogates.
For Journal of Biohacking builds
Highest-leverage interactive explanations
Ranked by mechanistic centrality, how badly static text fails, and misconception an interactive can permanently fix (§8 of corpus).
⚠ Lower priority / caution
Telomere shortening & epigenetic clocks are visually tempting but pedagogically risky — simple animations imply simple reversibility, which is precisely the unproven claim. If covered, visualize them as measurement interactives (how a clock is trained, what it does/doesn't prove), not as mechanisms an intervention “rewinds.”
Honesty box
Could not verify / open questions
TAME enrollment status conflicts
Some secondary pages state enrollment began in 2024; detailed 2026 audits state TAME has never enrolled and remains unfunded (~$45–75M needed). No TAME results exist under either account. Verify on ClinicalTrials.gov / AFAR at publication time. Sources in corpus: GrandpasAI vs Epithalon audit.
D+Q in MASH (2026, n=31) & RAPA-EX-01
Available only via secondary summaries at research time; verify primary papers before featuring.
From one detailed secondary investigation + corroborating tier summaries; “zero human trials” is solid, retraction specifics should be confirmed against journal notice / Retraction Watch before republication.
Unreported / recruiting as of Oct 2026 checks; status will change.
Reddit / forum representativeness
No Reddit/forum claim was verified as representative. Material is a qualitative study + labelled anecdote; prevalence, doses, and outcomes in the wider community cannot be quantified from it.
Scope notes
Audience reading level, article length, and jurisdiction were not specified in the mission; regulatory statements are US/FDA-centric because the primary literature and community sources are.
What this means for JoB
Lead with the Established core — fitness, sleep regularity, light & temperature — visualized at cell level (ETC, mitophagy, mTOR, SASP, circadian oscillators). Grade everything else in the open. That honesty is the beyond-baseline brand: superhuman ambition, without selling folklore as fact. Samples built from this corpus stay review-gated — nothing commits until Rehan approves.